KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies. - Suppr | 超能文献

KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.

作者信息

Bumol T F, Baker A L, Andrews E L, DeHerdt S V, Briggs S L, Spearman M E, Apelgren L D

机构信息

Lilly Research Laboratories, Indianapolis, Indiana.

出版信息

Targeted Diagn Ther. 1988;1:55-79.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.

Targeted Diagn Ther. 1988;1:55-79.

2

Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.

Cancer Res. 1990 Jun 15;50(12):3540-4.

3

Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.

J Pharmacol Exp Ther. 1987 May;241(2):695-703.

4

In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.

Cancer Res. 1990 Dec 1;50(23):7634-40.

5

Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.

Drug Metab Dispos. 1987 Sep-Oct;15(5):640-7.

6

Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.

Cancer Res. 1987 Jun 15;47(12):3118-22.

7

The use of anthracycline-antibody complexes for specific antitumor activity.

Targeted Diagn Ther. 1988;1:25-53.

8

Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.

Bioconjug Chem. 1993 Mar-Apr;4(2):121-6. doi: 10.1021/bc00020a003.

9

New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.

J Med Chem. 1989 Mar;32(3):548-55. doi: 10.1021/jm00123a007.

10

Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.

Targeted Diagn Ther. 1988;1:123-56.

引用本文的文献

1

Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice.

Histochem J. 1998 Oct;30(10):723-9. doi: 10.1023/a:1003486630314.

2

Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB.

Pharm Res. 1991 Oct;8(10):1264-9. doi: 10.1023/a:1015899612117.